A detailed history of Parallel Advisors, LLC transactions in Castle Biosciences Inc stock. As of the latest transaction made, Parallel Advisors, LLC holds 26,668 shares of CSTL stock, worth $566,961. This represents 0.02% of its overall portfolio holdings.

Number of Shares
26,668
Previous 26,968 1.11%
Holding current value
$566,961
Previous $581,000 1.55%
% of portfolio
0.02%
Previous 0.02%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 06, 2024

SELL
$18.06 - $25.3 $5,418 - $7,590
-300 Reduced 1.11%
26,668 $590,000
Q3 2023

May 20, 2024

SELL
$13.28 - $20.3 $1,155 - $1,766
-87 Reduced 0.32%
26,968 $455,000
Q3 2023

Nov 13, 2023

SELL
$13.28 - $20.3 $1,155 - $1,766
-87 Reduced 0.32%
26,968 $455,000
Q2 2023

May 20, 2024

BUY
$11.66 - $26.0 $58,136 - $129,636
4,986 Added 22.59%
27,055 $371,000
Q2 2023

Aug 04, 2023

BUY
$11.66 - $26.0 $58,136 - $129,636
4,986 Added 22.59%
27,055 $371,000
Q1 2023

May 20, 2024

SELL
$19.47 - $28.49 $89,542 - $131,025
-4,599 Reduced 17.25%
22,069 $501,000
Q4 2022

Feb 03, 2023

SELL
$18.08 - $30.0 $397 - $660
-22 Reduced 0.1%
22,069 $519,000
Q2 2022

Aug 01, 2022

BUY
$16.0 - $45.99 $2,912 - $8,370
182 Added 0.83%
22,091 $485,000
Q1 2022

Apr 28, 2022

BUY
$33.17 - $46.98 $4,643 - $6,577
140 Added 0.64%
21,909 $964,000
Q3 2021

Nov 02, 2021

SELL
$60.13 - $77.6 $1,322 - $1,707
-22 Reduced 0.1%
21,769 $1.45 Million
Q2 2021

Aug 06, 2021

BUY
$50.07 - $76.78 $89,675 - $137,512
1,791 Added 8.96%
21,791 $1.6 Million
Q1 2021

Apr 23, 2021

SELL
$58.92 - $97.33 $294,600 - $486,650
-5,000 Reduced 20.0%
20,000 $1.37 Million
Q4 2020

Feb 02, 2021

SELL
$43.6 - $73.05 $628,712 - $1.05 Million
-14,420 Reduced 36.58%
25,000 $1.68 Million
Q3 2020

Oct 27, 2020

BUY
$38.47 - $52.03 $747,087 - $1.01 Million
19,420 Added 97.1%
39,420 $2.03 Million
Q2 2020

Jul 16, 2020

BUY
$27.28 - $43.01 $545,600 - $860,200
20,000 New
20,000 $753,000

Others Institutions Holding CSTL

About CASTLE BIOSCIENCES INC


  • Ticker CSTL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Diagnostics & Research
  • Shares Outstandng 26,297,000
  • Market Cap $559M
  • Description
  • Castle Biosciences, Inc., a commercial-stage diagnostics company, focuses to provide diagnostic and prognostic testing services for dermatological cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma. The company als...
More about CSTL
Track This Portfolio

Track Parallel Advisors, LLC Portfolio

Follow Parallel Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Parallel Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Parallel Advisors, LLC with notifications on news.